Efficacy of a fixed combination of calcipotriol and betamethasone in the treatment of patients with psoriasis vulgaris


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In order to evaluate the effectiveness of therapy with a fixed combination of calcipotriol and betamethasone in the treatment of local psoriasis, 107 patients with psoriasis vulgaris of different localizations were examined. As a therapy, patients used a fixed combination of calcipotriol and betamethasone in the form of a gel once a day in different modes until a clinical remission or significant improvement was achieved or combination therapy, optionally including phototherapy. Thereafter, for the purpose of long-term control of the disease, the combined preparation was used as needed or by an intermittent scheme. The duration of the follow-up period was 1 year. Using monotherapy in 82.6% of patients, PAS1100 was achieved in 31 (67.4%), and PASI 75 - in 7 (15.2%) patients; using combined treatment, 38 (62.3%) patients achieved PAS1100, and 13 (21, 3%) - PASI 75. Depending on the method of application, 82.4% and 77.5% of patients managed to control the process during the year. The obtained results allow to draw a conclusion about high efficacy of this type of topical therapy in relieving exacerbations. The use of a fixed combination makes it possible to control the disease for a long time, which is accompanied by minimal side effects, a positive effect on the quality of life, and ease of use. The above mentioned components make the use of a fixed combination as the first-line method in the treatment of local psoriasis.

Full Text

Restricted Access

About the authors

L. S Kruglova

FSBIFPE “Central State Medical Academy" of the Administration of the President of the Russian Federation

Email: kruglovals@mail.ru
MD, Prof., Head of the Department of Dermatovenereology and Cosmetology

S. N Turbovskaya

FSBIFPE “Central State Medical Academy" of the Administration of the President of the Russian Federation

Department of Dermatovenereology and Cosmetology

References

  1. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-71.
  2. MacDonald A., Burden A.D. Psoriasis: advances in pathophysiology and management. Postgrad Med J. 2007;83(985):690-97.
  3. Потекаев Н.Н., Круглова Л.С. Псориатическая болезнь. М.: МДВ. 2014;264 с.
  4. Круглова Л.С., ТурбовскаяС.Н. Кальципотриол -современные возможности длительного контроля над псориазом в течение года. Клиническая дерматология и венерология. 2017;2:44-51.
  5. Круглова Л.С., Мордовцева В.В., Жукова О.В., Серов Д.Н. Комбинация кальципотриола и бетаметазона в лечении псориаза. Клиническая дерматология и венерология. 2014;6:54-64.
  6. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., Gottlieb A., Koo J.Y., Lebwohl M., Lim H.W., Van Voorhees A.S., Beutner K.R., Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3: guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-59.
  7. Nast A., Kopp I., Augustin M., Banditt K.B., Boehncke W.H., Follmann M., Friedrich M., Huber M., Kahl C., Klaus J., Koza J., Kreiselmaier I., Mohr J., Mrowietz U., Ockenfels H.M., Orzechowski H.D., Prinz J., Reich K., Rosenbach T., Rosumeck S., Schlaeger M., Schmid-Ott G., Sebastian M., Streit V., Weberschock T., Rzany B. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2007;299(3):111-38.
  8. Laws P.M., Young H.S. Topical treatment of psoriasis. Expert Opin Pharmacother. 2010;11(12):1999-2009.
  9. Bottomley J.M., Taylor R.S., Ryttov J. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence. Curr Med Res Opin. 2011;27(1):251-68.
  10. Girolomoni G., Vena G.A., Ayala F., Cannavà S.P., De Pità O., Chimenti S., Peserico A. Consensus on the use of the fixed combination calcipotriol/ betamethasone dipropionate in the treatment of plaque psoriasis. G Ital Dermatol Venereol. 2012;147(6):609-24.
  11. Fleming C., Ganslandt C., Guenther L., Johannesson A., Buckley C., Simon J.C., Stegmann H., Vestergaard Tingleff L. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20(4):465-71.
  12. White S., Vender R., Thaçi D., Haverkamp C., Naeyaert J.M., Foster R., Martinez Escribano J.A., Cambazard F., Bibby A. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol. 2006;7(3):177-84.
  13. Augustin M., Radtke M., van Engen A., Ruedig C., Lapp C., Moehling U. Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2009;7(4):329-38.
  14. Gamo R., López-Estebaranz JL. Terapia biológica y psoriasis. [Biologic therapy and psoriasis]. Actas dermo-sifiliogrâficas. 2006;97(1):1-17.
  15. Puig L., Carrascosa J.M., Carretero G., dela Cueva P., Lafuente-Urrez R.F., Belinchon I., Sánchez-Regaña M., García-Bustínduy M., Ribera M., Alsina M., Ferrándiz C., Fonseca E., García-Patos V., Herrera E., López-Estebaranz J.L., Marrón S.E., Moreno J.C., Notario J., Rivera R., Rodriguez-Cerdeira C., Romero A., Ruiz-Villaverde R., Taberner R., Vidal D. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Spanish evidencebased guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas dermo-sifiliogrâficas. 2013;104(8):694-709.
  16. Thaçi D., Ortonne J.P, Chimenti S., Ghislain P.D., Arenberger P., Kragballe K., Saurat J.H., Khemis A., Sprogel P., Esslinger H.U., Unnebrink K., Kupper H. A phase Illb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163(2):402-11.
  17. Kircik L.H. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial. J Drugs Dermatol. 2011;10(8): 878-82.
  18. Sticheriing M., Eicke C., Anger T. Practicability of combined treatment with calcipotriol/ betamethasone gel (Daivobet(R) Gel) and improvement of quality of life in patients with psoriasis. J Dtsch Dermatol Ges. 2013;11(5):420-27.
  19. Van de Kerkhof PCM. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol. 2004;151(3):663-68.
  20. Reich K., Bewley A. What is new in topical therapy for psoriasis? J Eur Acad Dermatol Venereol. 2011;25(4):15-20.
  21. Mason A.R., Mason J., Cork M., Dooley G., Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;3:CD005028.
  22. Fleming C., Ganslandt C., Guenther L., Johannesson A., Buckley C., Simon J.C., Stegmann H., Vestergaard Tingleff L. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20(4):465-71.
  23. White S., Vender R., Thaçi D., Haverkamp C., Naeyaert J.M., Foster R., Martinez Escribano J.A., Cambazard F., Bibby A. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol. 2006;7(3):177-84.
  24. Augustin M., Radtke M., van Engen A., Ruedig C., Lapp C., Moehling U. Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2009;7(4):329-38.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies